TG Therapeutics, Inc. Announces Follow-Up Data from the Triple Combination of Ublituximab, Umbralisib, and Bendamustine in Patients with DLBCL and FL at 60th American Society of Hematology Annual Meeting and Exposition
Dec 04, 2018
Below summarizes the data from the poster presentation.
Combination of Umbralisib, Ublituximab, and Bendamustine is Safe and Highly Active in Patients with Advanced DLBCL and Follicular Lymphoma (Abstract 4197)
This poster presentation includes data from patients with relapsed or refractory DLBCL or FL treated with the triple combination of umbralisib, ublituximab and bendamustine. Thirty-nine patients were evaluable for safety of which 38 were evaluable for efficacy (one patient discontinued due to a treatment-related adverse event (AE), neutropenia, prior to first efficacy assessment). Twenty-two patients (56%) were refractory to prior treatment. Overall, the triple combination was well tolerated and highly active in patients with advanced indolent and aggressive
Efficacy highlights from this poster include:
- 85% (11 of 13) ORR, including a 54% CR rate, observed in patients with relapsed or refractory FL
- 48% (12 of 25) ORR, including a 36% CR rate, observed in patients with relapsed or refractory DLBCL
The above referenced presentation is available on the Publications page, located within the Pipeline section, of the Company’s website at www.tgtherapeutics.com/publications.cfm.
Some of the statements included in this press release may be forward-looking statements that involve a number of risks and uncertainties. For those statements, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. In addition to the risk factors identified from time to time in our reports filed with the Securities and Exchange Commission, factors that could cause our actual results to differ materially are the following: our ability to successfully and cost effectively complete preclinical and clinical trials; the risk that the highlighted early clinical trial results, including the safety and efficacy results seen with the combination of ublituximab (TG-1101), umbralisib (TGR-1202) plus bendamustine that may have supported the acceptance of our data for presentation or influenced our decision to proceed with additional clinical trials, will not be reproduced in future studies or in the final presentations; the risk that the combination of ublituximab and umbralisib, referred to as U2 and being studied in the UNITY clinical trials, will not prove to be a safe and efficacious combination, or backbone for triple therapy combinations; the risk that data from the UNITY-
Senior Vice President,
Source: TG Therapeutics, Inc.